Axsome Therapeutics, Inc.
AXSM
$210.63
$2.811.35%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -6.96% | -8.63% | 61.88% | 26.89% | 39.54% |
| Total Depreciation and Amortization | 28.54% | 10.97% | 9.70% | 16.98% | 12.69% |
| Total Amortization of Deferred Charges | -48.26% | -76.16% | -77.26% | -76.49% | -50.55% |
| Total Other Non-Cash Items | -4.36% | 7.30% | -55.79% | -3.37% | 16.85% |
| Change in Net Operating Assets | 23.98% | 265.42% | -159.47% | 74.72% | -164.38% |
| Cash from Operations | -1.63% | 52.28% | 28.81% | 105.61% | -7.68% |
| Capital Expenditure | -3,361.54% | 64.20% | -136.67% | 35.56% | 75.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -3,361.54% | 64.20% | -136.67% | 35.56% | 75.00% |
| Total Debt Issued | -63.16% | -- | -- | -- | -- |
| Total Debt Repaid | 63.01% | -17,523.94% | -21,276.06% | -22,621.54% | -103,397.85% |
| Issuance of Common Stock | 25.17% | -55.50% | 19.62% | -23.72% | 146.01% |
| Repurchase of Common Stock | -219.14% | -114.51% | -95.87% | -78.01% | 33.13% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 48.85% | -25.35% | -23.70% | -22.43% | -200.90% |
| Cash from Financing | 39.38% | -89.77% | 15.03% | -30.05% | 140.24% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 600.09% | -23.43% | 80.49% | 90.48% | 113.34% |